MCOLN2 (Mucolipin-2) promotes autophagy to confer Adriamycin resistance in breast cancer by regulating mTOR degradation
Cellular Oncology · 2026-12 · 49 (6)
DOI: 10.1007/s13402-026-01270-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 03.08.2026. Verfasst von Hongyan Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biological Resource Bank, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Doxorubicin, Autophagy, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adriamycin is a cornerstone chemotherapeutic agent for advanced breast cancer, but its efficacy is frequently compromised by chemoresistance, a process in which macroautophagy is critically involved. However, the underlying mechanisms driving this autophagy-mediated resistance remain poorly understood.
Methods
Clinical data from patients with breast cancer who underwent chemotherapy were collected and the expression of MCOLN2 in tumor tissues was assessed. Using Adriamycin-resistant MCF-7/ADM cells and their parental MCF-7 cells, we investigated the role of MCOLN2 in regulating autophagic flux and mediating drug resistance. Key findings were further validated using an in vivo xenograft model.
Results
MCOLN2 expression was significantly upregulated in Adriamycin-resistant MCF-7/ADM cells and chemoresistant patient samples, where high levels correlated with poor prognosis. Knockdown of MCOLN2 sensitized MCF-7/ADM cells to Adriamycin both in vitro and in vivo, whereas its overexpression conferred resistance in parental MCF-7 cells. Mechanistically, MCOLN2 promoted autophagy, as evidenced by increased LC3-II levels and autophagosome formation. This pro-autophagic effect was mediated by MCOLN2-induced destabilization and lysosomal degradation of mTOR. Consequently, pharmacological or genetic inhibition of autophagy effectively reversed the MCOLN2-driven chemoresistance.
Conclusion
The MCOLN2-mTOR-autophagy axis has a critical role in the development of therapeutic resistance to Adriamycin in breast cancer. Targeting MCOLN2 could be a promising therapeutic strategy to overcome Adriamycin resistance in breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biological Resource Bank, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
- School of Biomedical Sciences and Li Ka Shing Institute of Health Science, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Radiation Oncology, Dalian Municipal Central Hospital, Dalian, China.
- College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
- Department of Blood Transfusion, The Third Affiliated Hospital of Sun Yat- sen University, Guangzhou, China.
- National Key Laboratory for Development and Utilization of Forest Food Resources, Zhejiang A&F University, Hangzhou, China.
Zitieren
APA
Yu, H., Wang, J., Ji, Y., Liu, X., Xie, M., Lo, C. Y., Cao, W., Zhou, H., Li, X., Huang, X., Jiang, L., Gu, X., Meng, X., & Yao, X. (2026). MCOLN2 (Mucolipin-2) promotes autophagy to confer Adriamycin resistance in breast cancer by regulating mTOR degradation. Cellular Oncology, 49(6). https://doi.org/10.1007/s13402-026-01270-x
Vancouver
Yu H, Wang J, Ji Y, Liu X, Xie M, Lo CY, et al. MCOLN2 (Mucolipin-2) promotes autophagy to confer Adriamycin resistance in breast cancer by regulating mTOR degradation. Cellular Oncology. 2026;49(6). doi:10.1007/s13402-026-01270-x
BibTeX
@article{Yu2026,
author = {Yu, Hongyan and Wang, Jie and Ji, Yongchen and Liu, Xiaofang and Xie, Mingxu and Lo, Chun Yin and Cao, Wenhan and Zhou, Huazhong and Li, Xiaoxue and Huang, Xiaoling and Jiang, Liwen and Gu, Xiaoqiong and Meng, Xiangqi and Yao, Xiaoqiang},
title = {MCOLN2 (Mucolipin-2) promotes autophagy to confer Adriamycin resistance in breast cancer by regulating mTOR degradation},
journal = {Cellular Oncology},
year = {2026},
volume = {49},
number = {6},
doi = {10.1007/s13402-026-01270-x}
}
EUVIMED